Luby S P, Qamruddin K, Shah A A, Omair A, Pahsa O, Khan A J, McCormick J B, Hoodbhouy F, Fisher-Hoch S
Community Health Sciences Department, Aga Khan University, Karachi, Pakistan.
Epidemiol Infect. 1997 Dec;119(3):349-56. doi: 10.1017/s0950268897007899.
To determine the prevalence and routes of transmission of hepatitis C virus (HCV) infection in Hafizabad, Pakistan, we collected sera in 1993 from a geographically based random sample of residents, and in 1994 identified 15 HCV-infected individuals (cases) and 67 age and sex matched uninfected individuals (controls). Initially we approached 504 households, and collected serum from a randomly selected household member in 309 (64%). Twenty persons (6.5%) had anti-HCV antibody; 31% percent had hepatitis B core antibodies, and 4.3% had hepatitis B surface antigen. In the case-control study, persons who received more therapeutic injections (categorized as averaging 1, 2-4, 5-9 or > 10 injections per year in the previous 10 years) were more likely to be infected with HCV (odds ratio 0, 1.5, 2.5 and 6.9 respectively, P = 0.008) compared to persons averaging 0 injections per year. Efforts to limit therapeutic injections to only those that are medically indicated and that use sterile equipment are essential in order to prevent transmission of HCV.
为确定巴基斯坦哈菲扎巴德丙型肝炎病毒(HCV)感染的流行情况及传播途径,我们于1993年从按地理位置随机抽取的居民样本中采集血清,并在1994年确定了15名HCV感染个体(病例)和67名年龄及性别匹配的未感染个体(对照)。最初我们走访了504户家庭,从其中309户(64%)中随机选择一名家庭成员采集血清。20人(6.5%)有抗HCV抗体;31%有乙肝核心抗体,4.3%有乙肝表面抗原。在病例对照研究中,与过去10年平均每年注射0次的人相比,接受更多治疗性注射的人(分类为过去10年平均每年1次、2 - 4次、5 - 9次或>10次注射)感染HCV的可能性更大(比值比分别为0、1.5、2.5和6.9,P = 0.008)。为预防HCV传播,将治疗性注射限制在仅医学上有必要且使用无菌设备的注射至关重要。